It was a cardiovascular outcomes trial, designed to determine whether semaglutide could prevent heart attacks, strokes, and cardiovascular death in overweight or obese individuals with established cardiovascular disease
Nutrition is central to my work across prevention and chronic disease management
Its part of a bigger picture that includes hormone support, sleep, and stress reduction. What the Latest Research Shows Evidence-Based and Backed by Science A 2024 study in The New England Journal of Medicine shows that patients on GLP-1 medications continued to lose weight for over a yearwith long-term maintenance when paired with expert oversight and lifestyle support
Clinical trials have shown that the use of a lower starting dose (2 mg) compared to a higher starting dose (4 mg) can partially reduce the frequency and severity of gastrointestinal side effects
GLP-1 receptor agonists (semaglutide, dulaglutide, liraglutide) work by mimicking a natural hormone that regulates blood glucose and appetite
doi: 10.1080/15548627.2015.1053680 67 ZhangJPavlovaNNThompsonCB
